Bio-Techne Dividend Update: Essential Details Before the Ex-Dividend Date on May 19th, 2025
Thursday, May 15, 2025 7:55 pm ET
1min read Bio-Techne Corporation (TECH) has announced its latest dividend details, with the ex-dividend date set for May 19th, 2025. The dividend announcement was made on May 7th, 2025, revealing that shareholders will receive a cash dividend of $0.080 per share on May 30th, 2025. This payout remains consistent with the company's previous dividend issued on Feb 28th, 2025, which was also $0.080 per share. The average dividend over the last ten distributions has been higher, at $0.272 per share, indicating that the current dividend is comparatively lower.
Recently, Bio-Techne has been actively engaging in strategic activities that could influence market performance and investor interest. The company is set to host a conference call on May 7th, 2025, to discuss its third-quarter fiscal 2025 financial results, highlighting recent developments in its operations. As of late, Bio-Techne has been showcasing its next-generation solutions in gene and cell therapy, emphasizing its leadership in advancing these technologies. Analysts have noted Bio-Techne's collaboration with Kytopen, focusing on an integrated cellular engineering workflow to expedite cell therapy manufacturing. This partnership underlines the company's commitment to enhancing scientific research and healthcare diagnostics.
Over the past week, Bio-Techne's stock price experienced a notable change, dropping to $47.86, marking a 7.27% decrease. This decline has sparked discussions regarding the company's market strategies and financial health. Since the last update, the corporation has also been awarded multiple G-Rex® Grants by ScaleReady, aimed at supporting researchers at prominent institutions like the University of Southern California and the Children's Hospital of Los Angeles. These initiatives reflect Bio-Techne's dedication to fostering innovation in biotechnology and supporting groundbreaking research.
As these developments unfold, investors should note that May 19th, 2025, is the crucial ex-dividend date. It marks the last opportunity for shareholders to purchase Bio-Techne's stock and qualify for the upcoming dividend. Any acquisition after this date will not entitle investors to the dividend for this period.
Recently, Bio-Techne has been actively engaging in strategic activities that could influence market performance and investor interest. The company is set to host a conference call on May 7th, 2025, to discuss its third-quarter fiscal 2025 financial results, highlighting recent developments in its operations. As of late, Bio-Techne has been showcasing its next-generation solutions in gene and cell therapy, emphasizing its leadership in advancing these technologies. Analysts have noted Bio-Techne's collaboration with Kytopen, focusing on an integrated cellular engineering workflow to expedite cell therapy manufacturing. This partnership underlines the company's commitment to enhancing scientific research and healthcare diagnostics.
Over the past week, Bio-Techne's stock price experienced a notable change, dropping to $47.86, marking a 7.27% decrease. This decline has sparked discussions regarding the company's market strategies and financial health. Since the last update, the corporation has also been awarded multiple G-Rex® Grants by ScaleReady, aimed at supporting researchers at prominent institutions like the University of Southern California and the Children's Hospital of Los Angeles. These initiatives reflect Bio-Techne's dedication to fostering innovation in biotechnology and supporting groundbreaking research.
As these developments unfold, investors should note that May 19th, 2025, is the crucial ex-dividend date. It marks the last opportunity for shareholders to purchase Bio-Techne's stock and qualify for the upcoming dividend. Any acquisition after this date will not entitle investors to the dividend for this period.
Disclaimer: The news articles available on this platform are generated in whole or in part by artificial intelligence and may not have been reviewed or fact checked by human editors. While we make reasonable efforts to ensure the quality and accuracy of the content, we make no representations or warranties, express or implied, as to the truthfulness, reliability, completeness, or timeliness of any information provided. It is your sole responsibility to independently verify any facts, statements, or claims prior to acting upon them. Ainvest Fintech Inc expressly disclaims all liability for any loss, damage, or harm arising from the use of or reliance on AI-generated content, including but not limited to direct, indirect, incidental, or consequential damages.
